Área Química Inorgánica, Programa de Posgrados, Facultad de Química, Universidad de la República, Gral. Flores 2124, 11800 Montevideo, Uruguay.
Dalton Trans. 2021 Feb 7;50(5):1651-1665. doi: 10.1039/d0dt03963b. Epub 2021 Jan 15.
In the search for a more effective chemotherapy for the treatment of Human African Trypanosomiasis, a disease caused by the parasite Trypanosoma brucei, the development of ferrocenyl compounds has arisen as a promising strategy. In this work, five new Pd-Fe heterobimetallic Pd(L)(dppf) compounds, including 8-hydroxyquinolyl derivatives HL1-HL5 as bioactive ligands and dppf = 1,1'-bis(diphenylphosphino)ferrocene as the organometallic co-ligand, were synthesized and fully characterized in the solid state and in solution. Molecular structures of three compounds were solved by single crystal X-ray diffraction methods. The compounds displayed submicromolar or micromolar IC values against bloodstream T. brucei (IC: 0.33-1.2 μM), and good selectivity towards the pathogen (SI: 4-102) with respect to mammalian macrophages (cell line J774). The new Pd complexes proved to be 2-fold to 45-fold more potent than the drug nifurtimox but most of them are less active than their Pt analogues. Potential molecular targets were studied. The complexes interact with DNA but they do not alter the intracellular thiol-redox homeostasis of the parasite. In order to understand and predict the main structural determinants on the anti-T. brucei activity, a search of quantitative structure-activity relationships (QSAR) was performed including all the M(L)(dppf) complexes, where M = Pd(ii) or Pt(ii), currently and previously developed by us. The correlation obtained shows the relevance of the electronic effects, the lipophilicity and the type of metal. According to the QSAR study, compounds with electron-withdrawing ligands, higher lipophilicity and harboring Pt would result in higher T. brucei cytotoxicity. From the whole series of M(L)(dppf) compounds developed, where M = Pt(ii) or Pd(ii) and HL = 8-hydroxyquinolyl derivatives, Pt-dppf-L4 (IC = 0.14 μM, SI = 48) was selected to perform an exploratory pre-clinical study in infected mice. This hit compound lacks acute toxicity when applied to animals in the dose/regimen described and exerts an anti-proliferative effect on parasites, which extends animal survival but is not curative.
在寻找更有效的化疗药物治疗非洲人类锥虫病(一种由寄生虫布氏锥虫引起的疾病)时,铁芳基化合物的开发已成为一种有前途的策略。在这项工作中,合成了五个新的 Pd-Fe 杂双金属Pd(L)(dppf)化合物,其中包括 8-羟基喹啉衍生物 HL1-HL5 作为生物活性配体和 dppf = 1,1'-双(二苯基膦)二茂铁作为有机金属共配体,并在固态和溶液中进行了充分的表征。通过单晶 X 射线衍射方法解决了三个化合物的分子结构。这些化合物对血液传播的 T. brucei 具有亚微摩尔或微摩尔的 IC 值(IC:0.33-1.2 μM),并且对病原体具有良好的选择性(相对于哺乳动物巨噬细胞(J774 细胞系)的 SI:4-102)。新的 Pd 配合物的效力比药物硝呋替莫高 2 到 45 倍,但大多数配合物的活性都低于其 Pt 类似物。研究了潜在的分子靶标。这些配合物与 DNA 相互作用,但不改变寄生虫细胞内的硫醇氧化还原稳态。为了理解和预测抗 T. brucei 活性的主要结构决定因素,我们对包括我们目前和以前开发的所有M(L)(dppf)配合物进行了定量构效关系(QSAR)搜索,其中 M = Pd(ii)或 Pt(ii)。得到的相关性表明了电子效应、亲脂性和金属类型的相关性。根据 QSAR 研究,具有吸电子配体、更高亲脂性和含有 Pt 的化合物将导致更高的 T. brucei 细胞毒性。在所开发的整个M(L)(dppf)化合物系列中,其中 M = Pt(ii)或 Pd(ii)和 HL = 8-羟基喹啉衍生物,选择 Pt-dppf-L4(IC = 0.14 μM,SI = 48)在感染的小鼠中进行探索性临床前研究。该命中化合物在所述剂量/方案下应用于动物时无急性毒性,并对寄生虫具有抗增殖作用,可延长动物存活时间,但不能治愈。